Servier Just Dropped $2.65 Billion on a Drug That Doesn't Exist Yet
French pharma giant Servier is paying up to $2.65 billion for a muscular dystrophy drug that hasn't even finished its pivotal trial. The bet: that protecting fragile muscles from damage, rather than fixing the underlying genetic defect, could become the backbone of treatment.
Imagine buying a house before the inspector even shows up. That's essentially what French pharma giant Servier just did, writing a check for up to $2.65 billion to acquire Edgewise Therapeutics' muscular dystrophy business. The crown jewel? A drug called sevasemten that hasn't been approved for anything, anywhere, and won't deliver pivotal trial results until later this year.
So either Servier knows something the rest of us don't, or muscular dystrophy just became the hottest zip code in rare disease.
The Deal: Big Upfront, Bigger Ambitions
Servier is paying $1.55 billion in cash at closing, with another $1.1 billion in milestones tied to regulatory approvals and commercial performance. The structure tells you a lot about where the risk sits. Duchenne muscular dystrophy (DMD) approval alone would trigger a $600 million milestone. Becker muscular dystrophy (BMD) approval adds up to $200 million more. And if annual U.S. net sales ever cross $550 million, Edgewise gets another $300 million on top.
The deal was announced June 1, 2026, and should close in the third quarter, pending standard regulatory clearance. Both boards have signed off.
For Edgewise, this is the biotech equivalent of selling your starter company to fund the dream. The Boulder, Colorado company pockets massive upfront cash and pivots entirely to its cardiovascular pipeline (more on that later). For Servier, it's a calculated bet that sevasemten will become the first targeted therapy for Becker muscular dystrophy, a condition with zero approved disease-modifying treatments.
What Sevasemten Actually Does
To understand why anyone would pay billions for this drug, you need to understand the problem it's trying to solve.
In muscular dystrophies like Becker and Duchenne, muscles lack a key protein called dystrophin. Without it, muscle fibers are fragile. Every time you contract a muscle forcefully, you're essentially punching a wall made of tissue paper. Over time, that repeated damage destroys muscle tissue, replacing it with scar tissue and fat.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Sevasemten doesn't try to restore dystrophin. Instead, it takes a completely different approach: it dials down the force of muscle contractions so the fragile fibers stop getting beaten up. Think of it like putting a speed limiter on a car with bad brakes. You're not fixing the brakes, but you're preventing the crash.
Technically, sevasemten is a fast skeletal myosin inhibitor. It selectively targets the molecular motor in fast-twitch muscle fibers (the ones responsible for quick, powerful movements) and reduces peak contraction force. Crucially, it doesn't affect cardiac muscle or overall voluntary strength. Patients aren't weaker; their muscles are just better protected.
The Clinical Story So Far
Sevasemten's data package isn't massive, but it's compelling enough to justify Servier's gamble.
In an early Phase 1b trial with Becker patients, creatine kinase (CK) levels dropped by about 71% after two weeks of treatment. CK is a blood marker of muscle damage, so a 71% reduction is like watching a building fire suddenly lose most of its flames. Fast-fiber troponin I, another muscle damage marker, plunged even further.
The longer-term data is where things get really interesting. In the ARCH open-label study, 12 adults with Becker took sevasemten for two years. Their NSAA scores (a standard walking and movement test, essentially measuring how well patients can do everyday physical tasks) stayed 3.1 points above what you'd expect from the disease's natural decline. In Becker, where patients typically lose ground year after year, standing still counts as a win.
The MESA extension study pushed follow-up out to 3.5 years, showing sustained stabilization. Some patients who switched from placebo to sevasemten even started trending upward. The cardiac safety profile also looked clean: no negative effects on heart function, and some subgroups actually showed improvement in heart pumping efficiency.
The Pivotal Bet: GRAND CANYON
All of this sets the stage for GRAND CANYON, the Phase 3 trial that will make or break the deal. It's a global, placebo-controlled study with approximately 175 patients, measuring NSAA scores over 18 months. The trial is described as "highly powered" to detect a statistically significant difference.
Top-line results are expected in Q4 2026. If the data hit, Edgewise (now Servier) plans to file a marketing application in the first half of 2027, seeking approval as the first targeted therapy for Becker. If the data miss, well, Servier just spent $1.55 billion on a very expensive science experiment.
There's also a Duchenne program further behind. Phase 2 trials called LYNX (ages 4 to 9) and FOX (kids who've already received gene therapy) have shown encouraging biomarker results and helped identify 10 mg once daily as the Phase 3 dose. But the Duchenne Phase 3 hasn't started yet, and its execution now falls entirely on Servier's shoulders.
Why Servier, and Why Now?
Servier isn't a household name in the U.S., but the privately held French company has been on an acquisition tear. Earlier in 2026, it agreed to buy Day One Biopharmaceuticals for $2.5 billion to expand in rare pediatric cancers. It grabbed KER-0193 from Kaerus Bioscience for up to $450 million to enter the Fragile X syndrome space. The pattern is clear: Servier is building a rare disease empire, one deal at a time.
The company has identified six priority clusters in rare neurology, and neuromuscular disorders are explicitly on the list. Sevasemten fills a gap that Servier couldn't fill internally. With 15 neurology programs in its pipeline but nothing specifically targeting muscular dystrophy, this acquisition gives them a late-stage asset with a clear path to market.
The commercial opportunity backs up the strategy. The global muscular dystrophy treatment market is projected at $5.22 billion in 2026, growing to $10.83 billion by 2033. DMD alone accounts for roughly $3.1 billion. More than 75 companies are developing treatments, but most target specific genetic mutations. Sevasemten's mutation-agnostic approach (it works regardless of which dystrophin mutation a patient carries) could make it a foundational therapy layered underneath everything else.
What Happens to Edgewise?
Wall Street loved the deal. Edgewise's stock jumped about 18% to a record high near $40 per share, adding roughly $656 million in market cap. Raymond James raised its price target to $66, calling the transaction "strongly positive." JPMorgan bumped to $53, noting the stock still hadn't fully priced in the Servier cash.
Several analysts described the muscular dystrophy program as an "overhang" that obscured the real story: EDG-7500, Edgewise's cardiac drug for hypertrophic cardiomyopathy. With $1.55 billion in upfront cash headed its way, Edgewise now has an almost embarrassingly long financial runway to pursue its heart failure ambitions without needing to raise money.
The Bottom Line
This deal is a referendum on two things: whether sevasemten's mechanism (protecting fragile muscles rather than trying to fix them) truly works in a pivotal setting, and whether Servier can execute in a therapeutic area where it has no track record.
The GRAND CANYON results in Q4 2026 will answer the first question. The second one will take years. But at $2.65 billion, Servier clearly isn't hedging. They're all in on the idea that the best way to treat muscular dystrophy might not be rebuilding the wall; it might be teaching the body to stop punching it.
Deals & M&A4 min read
Eli Lilly Just Spent $6.3 Billion to Fix a Problem You Didn't Know It Had
Eli Lilly is paying up to $7.8 billion for Centessa Pharmaceuticals and its experimental sleep disorder drugs. It's the biggest signal yet that the GLP-1 king is building a second empire, and the orexin agonist race just got a lot more interesting.
